Fortvita Biologics
Fortvita Receives Its First Positive CHMP Opinion, Recommending Zybrivo® (sintilimab) for First-Line Treatment of Non-Squamous Non-Small Cell Lung Cancer
The opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) is Fortvita's first European regulatory…
